Syndax Pharmaceuticals (SNDX)
19.04
0.00 (0.00%)
Upcoming Events
Latest Headlines
Stifel Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
June 15, 2026 9:32 AM - StreetInsider
Form 4 Syndax Pharmaceuticals For: Jun 11 Filed by: Botwood Nicholas A.J.
June 12, 2026 5:10 PM - SEC Filing
Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.
June 12, 2026 4:11 PM - SEC Filing
Syndax Pharmaceuticals (SNDX) PT Lowered to $31 at Guggenheim
June 12, 2026 6:54 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
June 12, 2026 6:53 AM - StreetInsider
Form 144 Syndax Pharmaceuticals Filed by: Botwood Nicholas A.J.
June 11, 2026 4:13 PM - SEC Filing
Syndax presents Revuforj clinical data across acute leukemia subtypes
June 11, 2026 7:03 AM - StreetInsider
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
June 11, 2026 7:03 AM - StreetInsider
Syndax publishes SAVE trial data on Revuforj combination therapy in AML
June 11, 2026 7:02 AM - StreetInsider
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Cl
June 11, 2026 7:00 AM - StreetInsider
Syndax raises $250 million through convertible notes offering
June 10, 2026 5:08 PM - StreetInsider
Form 8-K Syndax Pharmaceuticals For: Jun 10
June 10, 2026 5:05 PM - SEC Filing
Form 8-K Syndax Pharmaceuticals For: Jun 10
June 10, 2026 4:16 PM - SEC Filing
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 4, 2026 4:01 PM - StreetInsider
Form DEFA14A Syndax Pharmaceuticals
June 4, 2026 8:37 AM - SEC Filing
Form 8-K Syndax Pharmaceuticals For: Jun 03
June 4, 2026 7:16 AM - SEC Filing
Syndax raises $250 million through convertible notes offering
June 4, 2026 7:00 AM - StreetInsider
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
June 4, 2026 7:00 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) Reiterated at Buy by Stifel
June 3, 2026 7:00 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Syndax Pharmaceuticals (SNDX)
June 3, 2026 6:52 AM - StreetInsider
Form 4 Syndax Pharmaceuticals For: Jun 01 Filed by: Goldan Keith A.
June 2, 2026 4:30 PM - SEC Filing
Form 4 Syndax Pharmaceuticals For: Jun 01 Filed by: Metzger Michael A
June 2, 2026 4:30 PM - SEC Filing
SYNDAX highlights revumenib post-transplant data at ASCO 2026
June 2, 2026 4:01 PM - StreetInsider
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data
June 2, 2026 4:01 PM - StreetInsider
Form 144 Syndax Pharmaceuticals Filed by: Goldan Keith A.
June 1, 2026 3:59 PM - SEC Filing
Form 144 Syndax Pharmaceuticals Filed by: Metzger Michael A
June 1, 2026 3:55 PM - SEC Filing
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 1, 2026 7:00 AM - Globe NewsWire
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
June 1, 2026 7:00 AM - StreetInsider
Syndax gets four Revuforj abstracts accepted for ASCO 2026
May 21, 2026 5:01 PM - StreetInsider
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
May 21, 2026 5:01 PM - StreetInsider
Syndax Announces Participation in Upcoming Investor Conferences
May 20, 2026 7:00 AM - Globe NewsWire
Form SCHEDULE 13G/A Syndax Pharmaceuticals Filed by: Point72 Asset Management, L.P.
May 15, 2026 4:26 PM - SEC Filing
Syndax Pharmaceuticals (SNDX) PT Lowered to $37 at UBS
May 13, 2026 8:42 AM - StreetInsider
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
May 12, 2026 10:31 AM - StreetInsider
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 6, 2026 4:01 PM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Raised to $46 at Stifel on Revuforj Confidence
May 4, 2026 7:24 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Raised to $46 at Stifel
May 1, 2026 4:10 PM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $37 at Jefferies
May 1, 2026 3:12 PM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Raised to $29 at BofA Securities
May 1, 2026 4:38 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Raised to $37 at Barclays
May 1, 2026 2:47 AM - StreetInsider
Form ARS Syndax Pharmaceuticals For: Dec 31
April 30, 2026 5:26 PM - SEC Filing
Form DEFA14A Syndax Pharmaceuticals
April 30, 2026 5:24 PM - SEC Filing
Form DEF 14A Syndax Pharmaceuticals For: Apr 30
April 30, 2026 5:21 PM - SEC Filing
Syndax Pharmaceuticals (SNDX) Tops Q1 EPS by 14c
April 30, 2026 4:28 PM - StreetInsider
Form 10-Q Syndax Pharmaceuticals For: Mar 31
April 30, 2026 4:07 PM - SEC Filing
Form 8-K Syndax Pharmaceuticals For: Apr 30
April 30, 2026 4:04 PM - SEC Filing
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
April 30, 2026 4:01 PM - StreetInsider
Form SCHEDULE 13G Syndax Pharmaceuticals Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 1:53 PM - SEC Filing
Syndax to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on April 30, 2026
April 24, 2026 7:00 AM - Globe NewsWire
Syndax Pharmaceuticals (SNDX) spreader of 1500 contracts of June 24 calls, June 30 calls and June 18 puts
April 23, 2026 2:16 PM - StreetInsider
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 3, 2026 4:01 PM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Raised to $34 at Goldman Sachs
April 1, 2026 6:18 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $43 at Mizuho
March 30, 2026 8:57 AM - StreetInsider
Syndax Pharmaceuticals (SNDX) PT Lowered to $40 at Jefferies
March 27, 2026 4:14 PM - StreetInsider
Form SCHEDULE 13G/A Syndax Pharmaceuticals Filed by: VANGUARD GROUP INC
March 27, 2026 1:16 PM - SEC Filing
Full Article List
